Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2023) 14:531–552 https://doi.org/10.1007/s13300-023-01371-y
There are few errors in the original publication; the fourth author name is published as Nicolai R. Rhee, Novo Nordisk, Bangkok, Denmark. The correct name and affiliation is “Nicolai A. Rhee, Novo Nordisk, Bangkok, Thailand”.
There is an update in legend for Fig. 2. The correct legend given below.
Probabilistic sensitivity analysis of add-on liraglutide compared to standard of care alone in all people with type 2 diabetes and high cardiovascular risk. QALY quality-adjusted life-year, THB Thai baht
The Fig. 4 with updated legend is given below.
Probabilistic sensitivity analysis of add-on liraglutide compared to standard of care alone in people without atherosclerotic cardiovascular disease. QALY quality-adjusted life-year, THB Thai baht
The Fig. 5 with updated legend is below.
Cost-effectiveness acceptability curves of three cohort populations. ASCVD atherosclerotic cardiovascular disease, QALY quality-adjusted life-year, THB Thai baht
The Fig. 6 with updated legend is given below.
Tornado diagram of add-on liraglutide compared to standard of care alone in all people with type 2 diabetes. CV cardiovascular, ICER incremental cost-effectiveness ratio, MI myocardial infarction, QALY quality-adjusted life-year, RRT renal replacement therapy, SoC standard of care, THB Thai baht
The updated Fig. 7 is given below.
Tornado diagram of add-on liraglutide compared to standard of care alone in people with atherosclerotic cardiovascular disease. CV cardiovascular, ICER incremental cost-effectiveness ratio, MI myocardial infarction, QALY quality-adjusted life-year, RRT renal replacement therapy, SoC standard of care, THB Thai baht
The Fig. 8 with updated legend is below.
Tornado diagram of add-on liraglutide compared to standard of care alone in people without atherosclerotic cardiovascular disease. CV cardiovascular, ICER incremental cost-effectiveness ratio, MI myocardial infarction, QALY quality-adjusted life-year, RRT renal replacement therapy, SoC standard of care, THB Thai baht
The original article has been updated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Deerochanawong, C., Krittayaphong, R., Romano, J.G.U. et al. Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes Ther 14, 947–949 (2023). https://doi.org/10.1007/s13300-023-01392-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-023-01392-7